UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 30

Sortiert nach

Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial

Journal of clinical oncology, 2000-06, Vol.18 (11), p.2234-2244

2000

Volltextzugriff (PDF)

Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Randomized Double-Blind Trial

Journal of clinical oncology, 2000-04, Vol.18 (7), p.1399-1411

2000

Volltextzugriff (PDF)

Aromatase Inhibitors: Are There Differences Between Steroidal and Nonsteroidal Aromatase Inhibitors and Do They Matter?

The oncologist (Dayton, Ohio), 2008-08, Vol.13 (8), p.829-837

2008

Volltextzugriff (PDF)

Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone

Breast cancer research and treatment, 2009-02, Vol.113 (3), p.491-499

2009

Volltextzugriff (PDF)

Synthesis of exemestane labelled with (13)C

Steroids, 2008-08, Vol.73 (7), p.760-764

2008

Volltextzugriff (PDF)

Pharmacokinetics and Dose Finding of a Potent Aromatase Inhibitor, Aromasin (Exemestane), in Young Males

The journal of clinical endocrinology and metabolism, 2003-12, Vol.88 (12), p.5951-5956

2003

Volltextzugriff (PDF)

Synthesis of exemestane labelled with 13C

Steroids, 2008-08, Vol.73 (7), p.760-764

2008

Volltextzugriff (PDF)

A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation

British journal of clinical pharmacology, 2005-03, Vol.59 (3), p.355-364

2005

Volltextzugriff (PDF)

The Effect of Tamoxifen or Exemestane on Bone Mineral Density During the First 2 Years of Adjuvant Treatment of Postmenopausal Women with Early Breast Cancer

Clinical breast cancer, 2008-12, Vol.8 (6), p.527-532

2008

Volltextzugriff (PDF)

Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women

Cancer research (Chicago, Ill.), 1992-11, Vol.52 (21), p.5933-5939

1992

Volltextzugriff (PDF)

Effect of early treatment of prostate cancer with the 5α-reductase inhibitor turosteride in Dunning R3327 prostatic carcinoma in rats

The Prostate, 1998-06, Vol.35 (4), p.237-242

1998

Volltextzugriff (PDF)

Reproductive toxicity of exemestane, an antitumoral aromatase inactivator, in rats and rabbits

Reproductive toxicology (Elmsford, N.Y.), 2001-03, Vol.15 (2), p.195-213

2001

Volltextzugriff (PDF)

Biochemical and pharmacogenetic dissection of human steroid 5??-reductase type II

Pharmacogenetics (London), 2000-07, Vol.10 (5), p.407-413

2000

Volltextzugriff (PDF)

Erratum to “reproductive toxicity of exemestane, an antitumoral aromatase inactivator, in rats and rabbits” : [Reprod. Toxic. 15 (2001) 195–213]

Reproductive toxicology (Elmsford, N.Y.), 2001-09, Vol.15 (5), p.601-602

2001

Volltextzugriff (PDF)

Combined treatment of Dunning R3327 rat prostatic tumor with the 5α-reductase inhibitor PNU 157706 and the antiandrogen bicalutamide

Cancer chemotherapy and pharmacology, 2000-01, Vol.45 (1), p.31-37

2000

Volltextzugriff (PDF)

Synthesis and aromatase inhibition by potential metabolites of exemestane (6-methylenandrosta-1,4-diene-3,17-dione)

Steroids, 1993-11, Vol.58 (11), p.527-532

1993

Volltextzugriff (PDF)

Exemestane Improves Survival in Metastatic Breast Cancer: Results of a Phase III Randomized Study

Clinical breast cancer, 2000-09, Vol.1, p.S15-S18

2000

Volltextzugriff (PDF)

Effect of the 5[alpha]-Reductase Inhibitor PNU 156765, Alone or in Combination with Flutamide, in the Dunning R3327 Prostatic Carcinoma Model in Rats

Chemotherapy (Basel), 1998-07, Vol.44 (4), p.284

1998

Volltextzugriff (PDF)

Effect of the 5α-Reductase Inhibitor PNU 156765, Alone or in Combination with Flutamide, in the Dunning R3327 Prostatic Carcinoma Model in Rats

Chemotherapy (Basel), 1998-07, Vol.44 (4), p.284-292

1998

Volltextzugriff (PDF)

Comparison of the effects of the irreversible aromatase inhibitor exemestane with atamestane and MDL 18962 in rats with DMBA-induced mammary tumours

European journal of cancer & clinical oncology, 1991-01, Vol.27 (9), p.1145-1150

1991

Volltextzugriff (PDF)

Biochemical and pharmacogenetic dissection of human steroid 5α-reductase type II

Pharmacogenetics (London), 2000-07, Vol.10 (5), p.407-413

2000

Volltextzugriff (PDF)

Synthesis and antihypertensive activity of 2,4-dioxoimidazolidin-1-yl and perhydro-2,4-dioxopyrimidin-1-yl ergoline derivatives

Farmaco (Società chimica italiana : 1989), 1998-04, Vol.53 (4), p.293-304

1998

Volltextzugriff (PDF)

Synthesis and Biochemical Evaluation of the Novel Steroid Androsta-4,6,8(9)-Triene-3,17-Dione

Journal of enzyme inhibition, 1990, Vol.4 (2), p.121-129

1990

Volltextzugriff (PDF)

Synthesis and in vitro and in vivo evaluation of dopaminergic ergoline derivatives

Farmaco (Società chimica italiana : 1989), 1998-01, Vol.53 (1), p.65-72

1998

Volltextzugriff (PDF)

Is commercial “cerulein” always true cerulein?

Gastroenterology (New York, N.Y. 1943), 1980-05, Vol.78 (5), p.1113-1114

1980

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(30)

Sprache

Englisch
(30)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(22)
Science & Technology
(22)
Biological And Medical Sciences
(18)
Medical Sciences
(17)
Female
(15)
Pharmacology. Drug Treatments
(15)
Humans
(12)
Oncology
(10)
Animals
(8)
Antineoplastic Agents
(7)
Aromatase Inhibitors
(7)
Chemotherapy
(7)
Exemestane
(7)
Rats
(7)
Male
(6)
Pharmacology & Pharmacy
(6)
Administration, Oral
(5)
Aged
(5)
Androstadienes - Administration & Dosage
(5)
Androstadienes - Therapeutic Use
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial

Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Randomized Double-Blind Trial

Aromatase Inhibitors: Are There Differences Between Steroidal and Nonsteroidal Aromatase Inhibitors and Do They Matter?

Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone

Synthesis of exemestane labelled with (13)C

Pharmacokinetics and Dose Finding of a Potent Aromatase Inhibitor, Aromasin (Exemestane), in Young Males

Synthesis of exemestane labelled with 13C

A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation

The Effect of Tamoxifen or Exemestane on Bone Mineral Density During the First 2 Years of Adjuvant Treatment of Postmenopausal Women with Early Breast Cancer

Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women

Effect of early treatment of prostate cancer with the 5α-reductase inhibitor turosteride in Dunning R3327 prostatic carcinoma in rats

Reproductive toxicity of exemestane, an antitumoral aromatase inactivator, in rats and rabbits

Biochemical and pharmacogenetic dissection of human steroid 5??-reductase type II

Erratum to “reproductive toxicity of exemestane, an antitumoral aromatase inactivator, in rats and rabbits” : [Reprod. Toxic. 15 (2001) 195–213]

Combined treatment of Dunning R3327 rat prostatic tumor with the 5α-reductase inhibitor PNU 157706 and the antiandrogen bicalutamide

Synthesis and aromatase inhibition by potential metabolites of exemestane (6-methylenandrosta-1,4-diene-3,17-dione)

Exemestane Improves Survival in Metastatic Breast Cancer: Results of a Phase III Randomized Study

Effect of the 5[alpha]-Reductase Inhibitor PNU 156765, Alone or in Combination with Flutamide, in the Dunning R3327 Prostatic Carcinoma Model in Rats

Effect of the 5α-Reductase Inhibitor PNU 156765, Alone or in Combination with Flutamide, in the Dunning R3327 Prostatic Carcinoma Model in Rats

Comparison of the effects of the irreversible aromatase inhibitor exemestane with atamestane and MDL 18962 in rats with DMBA-induced mammary tumours

Biochemical and pharmacogenetic dissection of human steroid 5α-reductase type II

Synthesis and antihypertensive activity of 2,4-dioxoimidazolidin-1-yl and perhydro-2,4-dioxopyrimidin-1-yl ergoline derivatives

Synthesis and Biochemical Evaluation of the Novel Steroid Androsta-4,6,8(9)-Triene-3,17-Dione

Synthesis and in vitro and in vivo evaluation of dopaminergic ergoline derivatives

Is commercial “cerulein” always true cerulein?

Suchergebnisse filtern